GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria

Phase 3

Completed

Conditions: Malaria, Vivax

Interventions: Drug: Matched-Placebo for Tafenoquine
Drug: Tafenoquine
Drug: Matched-Placebo for Primaquine
Drug: Primaquine
Drug: Dihydroartemisinin-piperaquine (DHA-PQP)
Drug: ACT plus PQ (Rescue medication)
Drug: PQ (End of study treatment)

First Posted Date: 2016-06-16

Last Posted Date: 2020-07-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 150

Registration Number: NCT02802501

Locations: 🇮🇩
GSK Investigational Site, Jakarta, Indonesia

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: UMEC/VI
Drug: TIO/OLO
Drug: Albuterol/salbutamol

First Posted Date: 2016-06-15

Last Posted Date: 2018-07-02

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 236

Registration Number: NCT02799784

Locations: 🇬🇧
GSK Investigational Site, Swinton, United Kingdom

A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects

Phase 1

Completed

Conditions: Irritable Bowel Syndrome

Interventions: Drug: GSK3179106
Drug: Matched Placebo

First Posted Date: 2016-06-14

Last Posted Date: 2017-01-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 46

Registration Number: NCT02798991

Locations: 🇦🇺
GSK Investigational Site, Adelaide, South Australia, Australia

A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects

Phase 1

Completed

Conditions: Neoplasms
Cancer

Interventions: Drug: GSK1795091
Drug: Placebo

First Posted Date: 2016-06-14

Last Posted Date: 2020-11-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 42

Registration Number: NCT02798978

Locations: 🇩🇪
GSK Investigational Site, Berlin, Germany

Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Placebo
Drug: GSK3196165
Drug: MTX
Drug: Folic (or folinic) acid

First Posted Date: 2016-06-14

Last Posted Date: 2021-01-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 39

Registration Number: NCT02799472

Locations: 🇵🇱
GSK Investigational Site, Wroclaw, Poland

A Study to Evaluate Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of Engerix™-B Kinder Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa During Infancy

Phase 4

Completed

Conditions: Hepatitis B

Interventions: Biological: Engerix-B Kinder

First Posted Date: 2016-06-14

Last Posted Date: 2020-01-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 302

Registration Number: NCT02798952

Locations: 🇩🇪
GSK Investigational Site, Neumuenster, Germany

Single and Repeated Dose Escalation Study of GSK2838232

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK2838232 PIB
Drug: GSK2838232 IR1
Drug: Placebo PIB
Drug: GSK2838232 IR2
Drug: Ritonavir

First Posted Date: 2016-06-10

Last Posted Date: 2017-01-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 62

Registration Number: NCT02795754

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis

Phase 2

Withdrawn

Conditions: Adenomyosis

Interventions: Drug: Epelsiban
Drug: Placebo

First Posted Date: 2016-06-09

Last Posted Date: 2017-01-18

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02794467

Locations: 🇺🇸
GSK Investigational Site, Houston, Texas, United States

A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma

Phase 2

Withdrawn

Conditions: Asthma

Interventions: Drug: Sirukumab
Drug: Placebo
Drug: Rescue medication

First Posted Date: 2016-06-09

Last Posted Date: 2018-08-31

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02794519

Locations: 🇪🇸
GSK Investigational Site, Santiago De Compostela. La Coruña., Spain

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

Phase 4

Completed

Conditions: Asthma

Interventions: Device: ELLIPTA DPI
Device: GSK MDI
Device: AZ MDI

First Posted Date: 2016-06-09

Last Posted Date: 2019-07-02

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 324

Registration Number: NCT02794480

Locations: 🇺🇸
GSK Investigational Site, Waco, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy